The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.
Century Therapeutics, a US-based cancer treatment developer exploiting research at Harvard and Stanford universities, has filed for an initial public offering on the Nasdaq Global Select Market.
The company has not yet set any financial terms and used a $100m placeholder amount.
Founded in 2018 and incubated by venture capital firm Versant Ventures, Century has built an allogeneic cell therapy platform to support the development of cancer immunotherapies. Its lead drug candidate, CNTY-101, is being developed to treat lymphoma,…
